Molecular testing in lung cancer: the time is now
- PMID: 20623207
- DOI: 10.1007/s11912-010-0118-z
Molecular testing in lung cancer: the time is now
Abstract
In the past few years, we have witnessed a revolution in the molecular understanding of non-small cell lung cancer. Major progress has also been made in the clinic, with the introduction of EGFR-targeted and anti-angiogenic therapies. These advances have led to the development of a multitude of commercially available prognostic and predictive biomarkers. In particular, EGFR mutation and EML4/ALK testing have reached clinical validation and are incorporated into current treatment paradigms. This overview will present the scientific background of the biology of the relevant biomarkers and the studies conducted for their clinical validation. The technical challenges and shortcomings of these assays are also discussed. Furthermore, ongoing biomarker-driven clinical studies and the appropriate clinical use of available tests will be reviewed to assist the clinician with the proper incorporation of molecular testing into the routine care of patients with non-small cell lung cancer.
Similar articles
-
Present and future molecular testing of lung carcinoma.Adv Anat Pathol. 2014 Mar;21(2):94-9. doi: 10.1097/PAP.0000000000000012. Adv Anat Pathol. 2014. PMID: 24508692 Review.
-
Predictive molecular markers of response to epidermal growth factor receptor(EGFR) family-targeted therapies.Curr Cancer Drug Targets. 2010 Dec;10(8):799-812. doi: 10.2174/156800910793357925. Curr Cancer Drug Targets. 2010. PMID: 20718710 Review.
-
EGFR and EML4-ALK Updated Therapies in Non-Small Cell Lung Cancer.Recent Pat Anticancer Drug Discov. 2016;11(4):393-400. doi: 10.2174/1574892811666160803090944. Recent Pat Anticancer Drug Discov. 2016. PMID: 27491402 Review.
-
EGFR-targeted therapies in lung cancer: predictors of response and toxicity.Pharmacogenomics. 2009 Jan;10(1):59-68. doi: 10.2217/14622416.10.1.59. Pharmacogenomics. 2009. PMID: 19102716 Free PMC article. Review.
-
Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.Clin Lung Cancer. 2020 May;21(3):e182-e190. doi: 10.1016/j.cllc.2019.11.006. Epub 2019 Nov 21. Clin Lung Cancer. 2020. PMID: 31839532
Cited by
-
Update in lung cancer and oncological disorders 2010.Am J Respir Crit Care Med. 2011 Aug 1;184(3):297-302. doi: 10.1164/rccm.201103-0370UP. Am J Respir Crit Care Med. 2011. PMID: 21804121 Free PMC article. No abstract available.
-
EGFR-mutated lung cancer: a paradigm of molecular oncology.Oncotarget. 2010 Nov;1(7):497-514. doi: 10.18632/oncotarget.186. Oncotarget. 2010. PMID: 21165163 Free PMC article. Review.
-
Accuracy of lung cancer staging in the multidisciplinary team setting.Transl Lung Cancer Res. 2020 Aug;9(4):1654-1666. doi: 10.21037/tlcr.2019.11.28. Transl Lung Cancer Res. 2020. PMID: 32953539 Free PMC article. Review.
-
An official American Thoracic Society/European Respiratory Society statement: the role of the pulmonologist in the diagnosis and management of lung cancer.Am J Respir Crit Care Med. 2013 Aug 15;188(4):503-7. doi: 10.1164/rccm.201307-1269ST. Am J Respir Crit Care Med. 2013. PMID: 23947517 Free PMC article.
-
Ethnic Differences, Lung Cancer Risk, and Association of NRF2 Gene Polymorphism with Gemcitabine-Based Chemotherapy.Cureus. 2024 Jul 18;16(7):e64849. doi: 10.7759/cureus.64849. eCollection 2024 Jul. Cureus. 2024. PMID: 39026573 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous